Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade
Authors:
Open Access
- 1 November 2015
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (11) , 1226-1229
Abstract
Importance Patients with stage T2 multilesion angiosarcomas of the scalp and face that are larger than 10 cm demonstrate a 2-year survival rate of 0%. To our knowledge, major therapeutic advances against this disease have not been reported for decades. Preclinical data indicate that blocking β-adrenergic signaling with propranolol hydrochloride disrupts angiosarcoma cell survival and xenograft angiosarcoma progression. Observations A patient presented with a β-adrenergic–positive multifocal stage T2 cutaneous angiosarcoma (≥20 cm) involving 80% of the scalp, left forehead, and left cheek, with no evidence of metastasis. The patient was immediately administered propranolol hydrochloride, 40 mg twice a day, as his workup progressed and treatment options were elucidated. Evaluation of the proliferative index of the tumor before and after only 1 week of propranolol monotherapy revealed a reduction in the proliferative index of the tumor by approximately 34%. A combination of propranolol hydrochloride, 40 mg 3 times a day, paclitaxel, 2 mg/m2infused weekly, and radiotherapy during the subsequent 8 months resulted in extensive tumor regression with no detectable metastases. Conclusions and Relevance Our data suggest that β-blockade alone substantially reduced angiosarcoma proliferation and, in combination with standard therapy, is effective for reducing the size of the tumor and preventing metastases. If successful, β-blockade could be the first major advancement in the treatment of angiosarcoma in decades.Keywords
This publication has 10 references indexed in Scilit:
- Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcomaecancermedicalscience, 2015
- Targeting of Beta Adrenergic Receptors Results in Therapeutic Efficacy against Models of Hemangioendothelioma and AngiosarcomaPLOS ONE, 2013
- Src activation by β-adrenoreceptors is a key switch for tumour metastasisNature Communications, 2013
- Propranolol for Severe Hemangiomas of InfancyNew England Journal of Medicine, 2008
- Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 casesAnnals of Oncology, 2007
- Cutaneous angiosarcoma: a case series with prognostic correlationJournal of the American Academy of Dermatology, 2004
- Management of angiosarcomaCurrent Oncology Reports, 2002
- Soft tissue sarcomas of the head and neck in adultsThe American Journal of Surgery, 1990
- Angiosarcoma of the face and scalp, prognosis and treatmentCancer, 1987
- Angiosarcoma of skin and soft tissue: A study of forty-four casesCancer, 1981